A Multicenter, Open-label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies
|Effective start/end date||6/7/21 → 5/31/26|
- MIRATI THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.